Cancer of Soft and Connective Tissues Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 6 studies associated with Cancer of Soft and Connective Tissues.
Here is a small sampling of Cancer of Soft and Connective Tissues studies by title:
- Biophysical Studies and In Vitro Effects of Tumor Cell Lines of Cannabidiol and Its Cyclodextrin Inclusion Complexes
- Cannabinoid Receptor 1 Is A Potential Drug Target For Treatment Of Translocation-positive Rhabdomyosarcoma
- Parents' Use Of Cocaine And Marijuana And Increased Risk Of Rhabdomyosarcoma In Their Children
Components of the Cancer of Soft and Connective Tissues Research Dashboard
- Dosing information available for Cancer of Soft and Connective Tissues
- Chemotype guidance for treating Cancer of Soft and Connective Tissues with cannabis
- Synopsis of cannabis research for Cancer of Soft and Connective Tissues
- Individual study details for Cancer of Soft and Connective Tissues
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Cannabinoids & Endocannabinoids
- Study Result
- Year of Publication
Overview - Cancer of Soft and Connective Tissues
Description of Cancer of Soft and Connective Tissues
Soft tissue sarcoma is a relatively rare form of cancer that develops in the connective tissue that surrounds, support and connects our body structures. There are over fifty subtypes of this cancer. For instance, rhabdomyosarcoma is a soft and connective tissue cancer. It is typically a fast-growing and highly malignant tumor found most often in children. It affects the connective tissue and is believed to begin in progenitor cells (similar to stem cells), which later differentiate into muscle cells. The most common location of rhabdomyosarcoma development is the head and neck, followed by the genitourinary tract. Allopaths traditionally suspect hereditary causes, and treatment is limited to chemotherapy, surgery, and radiation. The survival rate in the late 1960s was a mere 10% to 15%, but by 2000 it had risen to over 70%.
Cancer of Soft Tissues
ICD-10 Code: C49
Cancer of Soft and Connective Tissues Symptoms:
Lump, swelling, reduced range of motion in affected limb, occasional pain
Also known as:
Soft Tissue Sarcoma, Rhabdomyosarcoma
THC Interaction with Pharmaceutical Drugs
- THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example.
- THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin). Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
- Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
CBD Interaction with Pharmaceutical Drugs
- CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
- Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.